These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33743960)

  • 41. CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
    Deng C; Chen J; Guo S; Wang Y; Zhou Q; Li Z; Yang X; Yu X; Zhang Z; Zhou F; Han H; Yao K
    World J Urol; 2017 Aug; 35(8):1213-1221. PubMed ID: 28105499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
    Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
    Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Regulation of expression of pituitary tumor transforming gene 1 (PTTG1) by androgen in prostate cancer].
    Xin DQ; Zhu XH; Lai YQ; You R; Na YQ; Guo YL; Mao ZB
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):638-40. PubMed ID: 16378119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Downregulation of PTTG1 expression inhibits the proliferation and invasiveness and promotes the apoptosis of human prostate cancer LNCaP-AI cells].
    Cao XL; Wei YY; Song XM; Lu KQ; Yu WC; Chen YQ; Liu YL; Gao JP
    Zhonghua Nan Ke Xue; 2017 Jul; 23(7):589-597. PubMed ID: 29723450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
    Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance.
    Cai Z; Wu Y; Li Y; Ren J; Wang L
    Aging (Albany NY); 2018 Dec; 10(12):3702-3712. PubMed ID: 30513511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
    Locke JA; Nelson CC; Adomat HH; Hendy SC; Gleave ME; Guns ES
    J Steroid Biochem Mol Biol; 2009 Jul; 115(3-5):126-36. PubMed ID: 19442514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells.
    Misawa A; Takayama K; Urano T; Inoue S
    J Biol Chem; 2016 Aug; 291(34):17861-80. PubMed ID: 27342777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer].
    Wang J; Quan CY; Chang WL; Shang ZQ; Jiang N; Li B; Niu YJ
    Zhonghua Nan Ke Xue; 2015 Sep; 21(9):775-81. PubMed ID: 26552208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gli2 mediates the development of castration‑resistant prostate cancer.
    Xia L; Bouamar H; Gu X; Zeballos C; Qin T; Wang B; Zhou Y; Wang Y; Yang J; Zhu H; Zhang W; Houghton PJ; Sun LZ
    Int J Oncol; 2020 Jul; 57(1):100-112. PubMed ID: 32319599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Tinay I; Tan M; Gui B; Werner L; Kibel AS; Jia L
    Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
    Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.
    Hu CY; Wu KY; Lin TY; Chen CC
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA-144-3p inhibits cell proliferation and promotes apoptosis in castration-resistant prostate cancer by targeting CEP55.
    You B; Zhang KC
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7660-7670. PubMed ID: 30536308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.